Pfizer, BioNTech search U.S. emergency nod for COVID-19 vaccine in adolescents

Pfizer Inc and its German accomplice BioNTech SE stated on Friday they’ve requested the US Food and Drug Administration to develop the emergency use of their Covid-19 vaccine in adolescents aged 12 to fifteen.
In March, the drugmakers stated the vaccine was discovered to be secure, efficient and produced sturdy antibody responses in 12- to 15-year olds in a medical trial.

Whether Covid-19 vaccines work and are secure to make use of on kids is likely one of the massive questions drugmakers are attempting to reply. Inoculating kids and younger folks is taken into account a crucial step towards reaching “herd immunity” and taming the pandemic, based on consultants.

The firms plan to request related rulings by different regulatory authorities globally within the coming days.